AR033651A1 - Derivados de pirimidina-2,4,6-triona, composiciones farmaceuticas que contienen dichos compuestos y el empleo de los mismos para la manufactura de un medicamento - Google Patents

Derivados de pirimidina-2,4,6-triona, composiciones farmaceuticas que contienen dichos compuestos y el empleo de los mismos para la manufactura de un medicamento

Info

Publication number
AR033651A1
AR033651A1 ARP000105063A ARP000105063A AR033651A1 AR 033651 A1 AR033651 A1 AR 033651A1 AR P000105063 A ARP000105063 A AR P000105063A AR P000105063 A ARP000105063 A AR P000105063A AR 033651 A1 AR033651 A1 AR 033651A1
Authority
AR
Argentina
Prior art keywords
pyrimidine
compounds
manufacture
pharmaceutical compositions
derivatives
Prior art date
Application number
ARP000105063A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR033651A1 publication Critical patent/AR033651A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52Two oxygen atoms
    • C07D239/54Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Derivados de pirimidina-2,4,6-triona que comprenden compuestos de fórmula 1 en la cual R1 representa un radical fenilo, fenoxilo, feniltio, fenilsulfinilo, fenilsulfonilo, fenilamino o fenilmetilo, en donde la parte fenilo puede estar sustituida con uno o más átomos de halógeno, hidroxilo, alcoxilo de 1 a 6 átomos de carbono, alquilo de 1 a 6 átomos de carbono, ciano o grupos nitro y R2 representa un radical arilo o heteroarilo, opcionalmente substituido, con actividad como inhibidor de la metalo-proteinasa; composiciones farmacéuticas y el empleo de los mismos para la manufactura de un medicamento con actividad antitumoral y/o antimetastásica.
ARP000105063A 1999-10-01 2000-09-27 Derivados de pirimidina-2,4,6-triona, composiciones farmaceuticas que contienen dichos compuestos y el empleo de los mismos para la manufactura de un medicamento AR033651A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99119506 1999-10-01

Publications (1)

Publication Number Publication Date
AR033651A1 true AR033651A1 (es) 2004-01-07

Family

ID=8239103

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000105063A AR033651A1 (es) 1999-10-01 2000-09-27 Derivados de pirimidina-2,4,6-triona, composiciones farmaceuticas que contienen dichos compuestos y el empleo de los mismos para la manufactura de un medicamento

Country Status (29)

Country Link
US (1) US6498252B1 (es)
EP (1) EP1226128B1 (es)
JP (1) JP3848160B2 (es)
KR (1) KR100459975B1 (es)
CN (1) CN1157382C (es)
AR (1) AR033651A1 (es)
AT (1) ATE289595T1 (es)
AU (1) AU768309B2 (es)
BR (1) BR0014678A (es)
CA (1) CA2385863C (es)
CO (1) CO5210860A1 (es)
CZ (1) CZ20021535A3 (es)
DE (1) DE60018301T2 (es)
ES (1) ES2235955T3 (es)
HK (1) HK1050198A1 (es)
HU (1) HUP0202832A3 (es)
IL (1) IL148573A0 (es)
MA (1) MA26823A1 (es)
MX (1) MXPA02003192A (es)
NO (1) NO20021380D0 (es)
NZ (1) NZ517635A (es)
PE (1) PE20010659A1 (es)
PL (1) PL202680B1 (es)
RU (1) RU2248971C2 (es)
TR (1) TR200200858T2 (es)
UY (1) UY26362A1 (es)
WO (1) WO2001025217A1 (es)
YU (1) YU22102A (es)
ZA (1) ZA200201754B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716845B2 (en) * 2001-03-30 2004-04-06 Hoffmann-La Roche Inc. Barbituric acid derivatives
WO2003053940A1 (en) 2001-12-20 2003-07-03 Bristol-Myers Squibb Company Barbituric acid derivatives as inhibitors of tnf-$g(a) converting enzyme (tace) and/or matrix metalloproteinases
WO2004084903A1 (en) * 2003-03-27 2004-10-07 F. Hoffmann-La Roche Ag Use of a trioxopyrimidine for the treatment and prevention of ocular pathologic angiogenesis
WO2004084902A1 (en) * 2003-03-28 2004-10-07 F. Hoffmann-La Roche Ag Use of a trioxopyrimidine for the treatment of chronic wounds
JP4787240B2 (ja) * 2004-04-01 2011-10-05 ユニベルシテ・ド・リエージュ ピリミジン−2,4,6−トリオンのシクロデキストリン包接複合体
JP4584981B2 (ja) * 2004-04-01 2010-11-24 ユニベルシテ・ド・リエージュ 気管支炎症疾患の処置および予防のためのトリオキソピリミジンの使用
EP1632489A1 (en) * 2004-08-24 2006-03-08 University of Liege 5-(1,1'-Biphenyl)-4-yl-5-(4-(4-aminoacylphenyl)-piperazin)-1-yl-pyrimidine-2,4,6-trione derivatives, as inhibitors of zinc metallondopeptidases, their preparation and use.
RU2449994C1 (ru) * 2011-03-10 2012-05-10 Светлана Алексеевна Мещерякова 6-(4-бензилпиперазино)-1,3-диметилурацила дигидрохлорид, проявляющий биологическую активность
RU2598607C1 (ru) * 2015-07-16 2016-09-27 Федеральное государственное бюджетное образовательное учреждение высшего образования "Астраханский государственный университет" (Астраханский государственный университет) Способ получения 5-гетарилметиленпиримидин-2,4,6-трионов

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1246743B (de) * 1965-01-12 1967-08-10 Dresden Arzneimittel Verfahren zur Herstellung von 5-Phenyl-5-piperidinobarbitursaeuren
US4595700A (en) 1984-12-21 1986-06-17 G. D. Searle & Co. Thiol based collagenase inhibitors
GB8726714D0 (en) 1987-11-14 1987-12-16 Beecham Group Plc Compounds
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
US5239078A (en) 1990-11-21 1993-08-24 Glycomed Incorporated Matrix metalloprotease inhibitors
CA2073513A1 (en) 1990-12-03 1992-06-04 John Robert Porter Peptidyl derivatives
CA2058797A1 (en) 1991-02-01 1992-08-02 Michael John Broadhurst Amino acid derivatives
US5789434A (en) 1994-11-15 1998-08-04 Bayer Corporation Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors
TR199800990T2 (xx) 1995-12-08 1998-07-21 Agouron Pharmaceuticals, Inc. Metaloproteinaz inhibit�rleri, bunlar� i�eren farmas�tik bile�imler, bunlar�n farmas�tik kullan�mlar� ve bunlar�n �retiminde kullan�labilecek y�ntemler ve ara �r�nler.
DE19548624A1 (de) 1995-12-23 1997-06-26 Boehringer Mannheim Gmbh Neue Barbitursäure-Derivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US6350786B1 (en) * 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers

Also Published As

Publication number Publication date
WO2001025217A1 (en) 2001-04-12
AU7784900A (en) 2001-05-10
HUP0202832A2 (hu) 2003-02-28
IL148573A0 (en) 2002-09-12
NZ517635A (en) 2003-11-28
CN1374954A (zh) 2002-10-16
DE60018301T2 (de) 2006-04-06
NO20021380L (no) 2002-03-20
ES2235955T3 (es) 2005-07-16
BR0014678A (pt) 2002-07-23
PE20010659A1 (es) 2001-06-20
KR100459975B1 (ko) 2004-12-03
DE60018301D1 (de) 2005-03-31
MA26823A1 (fr) 2004-12-20
YU22102A (sh) 2004-11-25
EP1226128A1 (en) 2002-07-31
HUP0202832A3 (en) 2003-03-28
PL357385A1 (en) 2004-07-26
HK1050198A1 (en) 2003-06-13
JP3848160B2 (ja) 2006-11-22
UY26362A1 (es) 2001-04-30
CZ20021535A3 (cs) 2002-11-13
KR20020039356A (ko) 2002-05-25
TR200200858T2 (tr) 2002-07-22
ATE289595T1 (de) 2005-03-15
CO5210860A1 (es) 2002-10-30
US6498252B1 (en) 2002-12-24
CN1157382C (zh) 2004-07-14
ZA200201754B (en) 2003-06-02
PL202680B1 (pl) 2009-07-31
EP1226128B1 (en) 2005-02-23
JP2003511376A (ja) 2003-03-25
AU768309B2 (en) 2003-12-04
NO20021380D0 (no) 2002-03-20
CA2385863A1 (en) 2001-04-12
RU2248971C2 (ru) 2005-03-27
CA2385863C (en) 2009-04-14
MXPA02003192A (es) 2002-09-30

Similar Documents

Publication Publication Date Title
AR023423A1 (es) Derivados de adamantano, procedimientos para su preparacion, composicion farmaceutica, procedimiento para la preparacion de la composicion farmaceutica, yuso de dichos derivados para la manufactura de medicamentos
ES2192031T3 (es) Nuevas amidas aromaticas, su procedimiento de preparacion y su aplicacion como medicamentos.
AR011116A1 (es) Compuesto derivado de n-hidroxi-beta-sulfonil propionamida y composicion farmaceutica que lo contiene
BR0010476A (pt) Compostos derivados do 4,5,6,7-tetrahidroindazol e seu uso como agentes antitumorais
ECSP045004A (es) Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades andrógeno dependientes
PA8592001A1 (es) Activadores de glocoquinasa heteroaromaticos de seis miembros 5-sustituidos
SE0202463D0 (sv) Novel compounds
DK0931788T3 (da) Metalloproteasehæmmere
BR0206433A (pt) Composto, composição farmacêutica, processo para a prepapação de um composto, e, uso de um composto
BR9912073A (pt) Composições farmacêuticas que compreendem 2-quinolonas
AR066982A2 (es) Compuestos heteroaromaticos sustituidos como inhibidoress tirosin quinasa, composiciones farmaceuticas que los contiene y su uso en la preparacion de medicamentos
ECSP045253A (es) Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa
DE69814375D1 (de) Fungizide trifluoromethylalkylamino-triazolopyrimidine-derivate
BR0312464A (pt) Inibidores de tirosina quinases
AR024138A1 (es) Inhibidores de la proliferacion celular
CO5611155A2 (es) Uso de derivado de indolopirrolocarbazol y otro agente anticanceroso en combinacion
AR004498A1 (es) Compuestos de aminofosfonato y composiciones farmaceuticas que los contienen, el uso de los mismos, y un procedimiento para su preparacion
ECSP078062A (es) Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen
AR033651A1 (es) Derivados de pirimidina-2,4,6-triona, composiciones farmaceuticas que contienen dichos compuestos y el empleo de los mismos para la manufactura de un medicamento
BR0314352A (pt) Indóis 2,7-substituìdos e seu uso como moduladores de 5-ht6
AR033957A1 (es) Nuevos compuestos
BR0311491A (pt) Composto, composição farmacêutica, uso de um composto, e, método terapêutico para tratar câncer em um mamìfero
SE0300105D0 (sv) Diarylmethylidene piperdine derivatives, preparations thereof and uses thereof
UY27770A1 (es) Imidazolinilmetil aralquilsulfonamidas
ATE307131T1 (de) Phenanthrolin-7-onderivate und ihre therapeutische verwendung

Legal Events

Date Code Title Description
FA Abandonment or withdrawal